Brind.

Revvity agreed to sell its China Immunodiagnostics and ACD/Labs software business units, contributing to Q2 revenue growth.

1 report, 1 independent Updated Aug 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Revvity

Keep exploring

The entities involved

Revvity
American biotech company
- Revvity and Codexis, both healthcare companies, are currently competing against each other for market share.Sun 08:23
- Dovish remarks made on September 3, 2025, eased market concerns regarding high interest rates, involving the FED and Jerome Powell.Sun 01:44

Coverage

Newest first; wire copies grouped

Aug 1tickerreport.com